Upcoming event
EAU UROonco: A meeting steered by the EAU Section of Oncological Urology (ESOU)
Back

Tags

Article of the Month, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROwebinar, Webinar
Show all

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

The LANCET oncology, March 2024

View

Artificial intelligence links pre-operative multi-phase CT images to pathologic features, survival outcomes and biological behaviors of renal masses using real-world data

View
posters webcasts

Enhancing immunotherapy in renal cell carcinoma by engineering cytotoxic T lymphocytes with chimeric costimulatory switch proteins

View
webcasts

A potential tumor-marker from urinary microbiota – focusing on renal cell carcinoma

View
posters webcasts

Reclassification of small renal masses according to the EAU Guidelines newly-proposed TNM classification for suspected renal cell carcinoma: Implications for decision-making

View
posters webcasts

Active surveillance versus primary intervention for clinical T1a kidney tumors: Contemporary results after fourteen-year experience of the DISSRM prospective comparative study

View
webcasts

Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: Differential effectiveness by risk group?

European Urology Oncology, February 2024

View

Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC)

View

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)

The Lancet Oncology, January 2024

View

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial

View

First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma

View

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC

View
Next